Business Wire

Test of LED System that Warns Drivers of Black Ice Under Way in Susono, Japan

Share

Susono City, Stanley Electric Co., Ltd., Kaga FEI Co., Ltd., NTT Communications Corporation and Dassault Systèmes K.K.. announced jointly today that a system for warning drivers about transparent ("black") ice using a smart streetlight developed by the four companies is being tested on a public road in Susono, Japan from February 10 to March 31. The test will verify the effectiveness of the system in preventing car slippage and pedestrian falls in a public area of Susono.

For the test, a smart streetlight that projects an illuminated warning ("Caution Ice") on the road surface was installed on a light pole in front of Yanagibata Bridge in Ishiwaki, Susono City. During the test, data from an edge AI camera and sensors mounted on the smart streetlight are being collected and transmitted via mobile communication to a center for analysis, including by comparing the number of ice-related accidents at the site before and after the test. Also, residents will be surveyed to see if their awareness of ice-related hazards is changed by the operation of the system.

The roles of each company are as follow:

Stanley Electric:

  • Develop, manufacture and supply LED streetlight and illumination-projection equipment  

Kaga FEI:

  • Provide edge AI camera and sensors
  • Develop embedded AI system

NTT Communications:

  • Implement mobile communications (IoT Connect Mobile® TypeS1)
  • Provide platform for visualizing and storing collected data (Things Cloud®2)

Dassault Systèmes:

  • Provide virtual twin3 platform (3DEXPERIENCE© platform)
  • Build virtual twins, data visualization, and scenario analysis based on system and terrain data

Once the system is demonstrated to be fully reliable and effective, its broad deployment in other municipalities will be promoted along with the use of smart streetlights in emerging countries where road lighting is uncommon. In addition, by combining data from the system with weather data, etc., it will be possible to provide enhanced weather-related driving information, such as traffic congestion forecasts in areas where snow is expected, keeping drivers better informed while also supporting the work of road and traffic managers.

NTT Com's KOEL4 design studio will join the project to help research opportunities for commercial applications. It is expected that the system could be applied in business areas such as shopping malls and other commercial facilities as well as Park-PFI, a publicly solicited, privately financed initiative for the maintenance and management of urban parks in Japan.

Susono, which has adopted the slogan "Japan's most citizen-oriented city hall," is actively modernizing its urban areas through the introduction of universal-design pedestrian spaces, advanced technology and data analysis, aiming to realize zero fatalities and less than 200 injuries due to accidents per year by 2025.

1 IoT Connect Mobile® TypeS is an eSIM-based mobile data communication service.
2 Things Cloud® is an IoT platform that packages data collection, visualization, analysis and management functions via connected sensors and devices tailored to specific business environments.
3 Virtual twin, more than a digital copy of the real world, is a representation of the real world based on mathematical models and scientific principles.
4 The KOEL design studio was established in April 2020 within NTT Com's Innovation Center, which is dedicated to the creation of new businesses.

About Stanley Electric

Stanley Electric Co., Ltd. was founded in 1920 to manufacture and sell automotive light bulbs and other specialty light bulbs. Today, the company is highly regarded worldwide for products it supplies to major automobile manufacturers. Starting with the world's first commercial high-brightness LEDs in 1976, the company has developed numerous components and other electronic that contribute to safety and energy conservation, including smart streetlights. Please visit https://www.stanley.co.jp/

About Kaga FEI

Kaga FEI Co., Ltd. is an electronics trading company that sells consumer and industrial electronic devices and products for automobiles, AV equipment, communications equipment and information processing equipment. The company and its global partners also provide technical support and solution services that combine commercial products and technologies, including electronics manufacturing services, in markets worldwide. Please visit https://www.kagafei.com/jp/

About NTT Communications

NTT Communications solves global technology challenges by helping enterprises utilize managed IT-infrastructure solutions to overcome complexity and risk in their IT environments. These solutions are backed by our worldwide infrastructure, including industry-leading, global tier-1 public and private networks reaching over 190 countries/regions, and more than 500,000m2 of the world's most advanced data-center facilities. As the core provider of the DOCOMO group's enterprise-business services and solutions, we create value by providing global-scale support for restructuring in industry and society, new workstyles and digital transformation in communities. Together with NTT Ltd., NTT Data and NTT DOCOMO, we are the NTT Group.
www.ntt.com | Twitter@NTT Com | Facebook@NTT Com

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating 'virtual twin experiences’ of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production.
Dassault Systèmes’ 20,000 employees are bringing value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit https://www.3ds.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information
Susono
Business: Strategic Promotion Division
+81-55-995-1804; kikaku@city.susono.shizuoka.jp
Road management: Construction Management Division
+81-55-995-1855; kanri@city.susono.shizuoka.jp

Stanley Electric
Yokohama Technical Center, Lighting Application Division
+81-45-910-6629

Kaga FEI
Partner Business Promotion Department
System Business Center, Solutions Division
ml-snk_colbiz_pj@jp.kagafei.com

NTT Communications
Business Solution Division, Business Solution Department
bbx-5bs3g@ntt.com

Dassault Systèmes
Marketing Representative, Public Relations Division
+81-3-4321-3506; japan.marketing@3ds.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye